Precipio Inc (PRPO)

NASD · Healthcare · Diagnostics & Research · USA

Precipio Inc is a micro cap company (market value under $300 million) in the Diagnostics & Research industry.

Precipio is a healthcare biotechnology company specializing in cancer diagnostics for hematologic malignancies. It operates a pathology services division providing diagnostic testing to physicians and hospitals, and a products division developing proprietary diagnostic assays for other laboratories. The integrated structure enables the company to develop and validate diagnostic products while generating revenue from testing services.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Precipio Inc stock.

Our verdict on PRPO

Undervalued: intrinsic value $73.78 per share, market price $19.17, margin of safety 74.0% (as of 2026-11-17).

A 4.7x revenue multiple, discounted for its losses, values the shares at $73.78; the price of $19.17 is 74% below that value.

ETFs with the most weight in PRPO

4 more funds hold it; the full list is part of the paid plan.

More on PRPO

Browse

Peers in Diagnostics & Research

All 44 Diagnostics & Research stocks

Is PRPO undervalued or overvalued?

PRPO is undervalued (as of the 2026-11-17 close). A 4.7x revenue multiple, discounted for its losses, values the shares at $73.78; the price of $19.17 is 74% below that value.

What is the intrinsic value of PRPO?

$73.78 per share (as of the 2026-11-17 close), against a market price of $19.17. That is a margin of safety of 74.0%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.